Explore Kyverna through 3 example sentences from English. Ideal for language learners, writers and word enthusiasts.
Kyverna in a sentence
Using Kyverna
- In the example corpus, kyverna often appears in combinations such as: kyverna therapeutics.
Context around Kyverna
- Average sentence length in these examples: 20 words
- Position in the sentence: 2 start, 1 middle, 0 end
- Sentence types: 3 statements, 0 questions, 0 exclamations
Corpus analysis for Kyverna
- In this selection, "kyverna" usually appears near the start of the sentence. The average example has 20 words, and this corpus slice is mostly made up of statements.
- Around the word, therapeutics stand out and add context to how "kyverna" is used.
- Recognizable usage signals include kyverna therapeutics has and kyverna therapeutics is. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "kyverna" sits close to words such as aaaaand, aaah and aacl, which helps place it inside the broader word index.
Example types with kyverna
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Kyverna Therapeutics has higher revenue and earnings than Sana Biotechnology. (10 words)
Finally, Artal Group S.A. acquired a new stake in Kyverna Therapeutics during the 1st quarter valued at approximately $4,968,000. (22 words)
Kyverna Therapeutics is currently developing a new CAR-T cell therapy, KYV-101, that aims to “reset” the immune systems of patients with autoimmune diseases, according to Chung. (28 words)
Kyverna Therapeutics is currently developing a new CAR-T cell therapy, KYV-101, that aims to “reset” the immune systems of patients with autoimmune diseases, according to Chung. (28 words)
Finally, Artal Group S.A. acquired a new stake in Kyverna Therapeutics during the 1st quarter valued at approximately $4,968,000. (22 words)
Kyverna Therapeutics has higher revenue and earnings than Sana Biotechnology. (10 words)
Example sentences (3)
Finally, Artal Group S.A. acquired a new stake in Kyverna Therapeutics during the 1st quarter valued at approximately $4,968,000.
Kyverna Therapeutics has higher revenue and earnings than Sana Biotechnology.
Kyverna Therapeutics is currently developing a new CAR-T cell therapy, KYV-101, that aims to “reset” the immune systems of patients with autoimmune diseases, according to Chung.
Common combinations with kyverna
These word pairs occur most frequently in English texts: